循环肿瘤DNA监测早期肺癌术后微小残留病灶的研究进展

Circulating Tumor DNA in Predicting Minimal Residual Disease of Patients with Early-Stage Non-Small Cell Lung Cancer

循环肿瘤DNA(circulating tumor DNA,ctDNA)已经应用于监测转移性非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗。近来研究者开始关注ctDNA预测早期NSCLC患者根治术后微小残留病灶(minimal residual disease,MRD)的价值。全文总结目前常用的ctDNA检测方法,并介绍了其在早期肺癌术后评估MRD和复发预警方面的应用进展。

Circulating tumor DNA(ctDNA) has been widely used in monitoring efficacy of targeted therapy for metastatic non-small-cell lung cancer(NSCLC). Recent researches are focusing on the value of ctDNA in predicting minimal residual disease(MRD) of patients with early-stage cancer after treatment. This article reviews the techniques for detecting ctDNA and its application in monitoring MRD and recurrence in patients with early-stage NSCLC after radical resection.